Editas Medicine Inc at TD Cowen Healthcare Conference Transcript
Cowan's forty-sixth annual healthcare conference. I'm Phil Nado, one of the biotech analysts here at Cowan, and it's my pleasure to do a fireside chat with Editas. We have with us today Gilmore O'Neill, the President and CEO, and Linda Berkeley, the CSO.
Questions & Answers
Maybe I'll kick it to you guys to start. Could you give us a brief statement, state of the company overview? What are Eitas's biggest strengths, biggest challenges, and what does it need to do to create shareholder value over the next year? Sure.
' -
Phil, and thanks very much for having us here. It's great to be here with Linda and yourself. Edit has is a pre-clinical stage company which is on track to have human POC by the end of this year 2026 for our lead asset edit 401, which is a very exciting in vivo delivered editing strategy that in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
